What does the evidence say about Collagen Peptides Tendon Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Collagen Peptides Tendon Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Objective To evaluate clinical evidence on oral or injectable hydrolyzed collagen peptides, or related low-molecular-weight peptide preparations, in tendon and ligament injuries and post-repair/reconstruction settings. [Latini L (2026); evidence level 1] - Closely related disorders were included only as contextual evidence when direct injury-specific data were limited. [Latini L (2026); evidence level 1] - Three provided direct evidence in tear or post-surgical populations: one pilot study of injectable low-molecular-weight peptides in partial supraspinatus tendon tears, one randomized trial after ACL reconstruction, and one randomized trial after rotator cuff repair. [Latini L (2026); evidence level 1] - Background Low-molecular-weight hydrolyzed collagen peptides are increasingly used as adjuncts in musculoskeletal medicine, but their clinical role in tendon and ligament injuries remains unclear. [Latini L (2026); evidence level 1] - Background Lateral elbow tendinopathy (LET) is a common upper-limb musculoskeletal disorder causing pain during gripping activities, reduced work capacity, and functional limitation. [Vitale N (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.